Member Info for Dunnieboy

Rates Vir as a possible 5bagger plus some.
https://youtu.be/ihIDXEdZtUQ

ViR which trades on the Nasdaq is massively unvalued & well worth looking at.

Pharma giant Glaxosmith-kline got a shot in the arm after the US government ordered more of its Covid treatment.

The shares jumped 1.3 per cent, or 20.2p, to 1631.6p after it announced that it will deliver another 600,000 doses of sotrovimab to the US in the first quarter of 2022.

The antibody treatment is designed to prevent and reduce the severity of Covid-19 symptoms in patients, particularly those from high-risk groups.

The treatment, which mimics the body’s immune system, was developed with US biotech firm Vir, and has now attracted global orders totalling 1.7m doses.

Brilliant news.

Vir are being really cagey about releasing manufacturing figure which although frustrating it’s the sign of professionalism, they obviously want to build value into the share price as opposed to a bubble, Scangos the CEO has stated that he wants the company to be ‘acquisitive’ and a properly valued share price can help us raise funds(if needed) or use a mixture of new shares & cash in any ‘potential’ acquisition.
Saying that it looks like we could fund any acquisition out of ‘cash flow’. the way sales of Sotrovimab are going.

The one thing GSK & Vir need to do is update the market with regard to manufacturing, Vir originally said they intended to produce 2.4m, say they upped that to 10m then the sp should fly, certainly Vir’s.

French regulator says GSK Xevudy treatment promising against Omicron

Fri, 7th Jan 2022 15:43
PARIS, Jan 7 (Reuters) - French health regulator HAS said on
Friday that GSK's Xevudy treatment was promising against
COVID-19 variants such as Omicron as it gave the treatment early
access.

HAS said in a statement the drug featured a mechanism which
suggested that its efficacy could be maintained on variants of
the virus, including the Omicron variant.

(Reporting by Tassilo Hummel
Editing by GV De Clercq)

https://www.nasdaq.com/articles/3-covid-stocks-that-will-make-billions-in-2022

Papucel, shares are often about your point of entry, I got into VIR at $25 so I think it’s great even though I wish I traded it more, if I bought in at the blip up of $141 then I’d think it was a load of crap, we can all go on about being long term investors but that’s the reality ‘point of entry’.

45,000 x $2100= $94,500,000
https://www.news.com.au/technology/science/human-body/australia-secures-another-45000-doses-of-covid-treatment-sotrovimab/news-story/b251deb84ff5b8d253d0c609a0d1d8c3?amp

Papucel, I’ve been in Vir Bio for over 18months and although it’s been a rollercoaster I am quite happy to point out that we finished up 57% year to date, and before you point out it touched $141 at one point last year it was a blip caused by a massive short squeeze by the Reddit brigade, I’ll be quite happy to do 57% again at this point next year, although I wouldn’t mind selling some if we hit $141 again.

Denmark are running out now, we need news of a rapid ramp up in production.
The treatment Sotrovimab, which effectively prevents hospitalizations, is becoming a scarce commodity, writes DR.
The country's hospitals are running out of treatment drug Sotrovimab. An agent that effectively prevents admissions with the Omikron variant.
Jan Gerstoft, professor at the University of Copenhagen and chief physician at the Department of Infectious Diseases at Rigshospitalet, tells DR's Orientering on P1.

ALSO SEE
A weekday in a test center: - People are affected by insecurity again
Currently, there are only 850 treatments with the product left at the Capital Region's Pharmacy, which is the country's largest. From here, medicines are delivered to the country's hospitals

Sotrovimab is now one of only two treatments on offer by the NHS

Treatments for coronavirus (COVID-19)

The NHS is offering new antibody and antiviral treatments to people with coronavirus (COVID-19) who are at highest risk of becoming seriously ill.

2 types of COVID-19 treatment are available:

sotrovimab (Xevudy)
molnupiravir (Lagevrio)
Sotrovimab is a biological medicine. It is also known as a neutralising monoclonal antibody (nMAb).

I think you can look at the cost & think it’s expensive at £1500 but currently it’s only been produced in intravenous form and takes 30 min to administer and prevents hospitalisation & death by 85%, put that against the cost of being hospitalised and possibly being in intensive care.
The real ‘game changer’ is the intramuscular jab, quick to administer and can be done in vaccination suites, car parks etc, the im version has just been passed but no manufacturing figures have been announced, oh and the same efficacy of 85%.

recent interview, Bill Gates admitted that the existing COVID-19 vaccines that the world poured billions of dollars into producing have failed to control infection and transmission.

And then he made this astonishing statement...

"We need a new way of doing vaccines."

Sotrovimab is currently the most effective treatment on the market, with no reported safety issues.

Sotrovimab is also mentioned in the Mail on Sunday.

Sunday Times mentions Xevudy/Sotrovimab as a key tool if the world is to live with Covid.

$VIR
Task force press conference just said the US govt MORE THAN DOUBLING the order to OVER 1 MILLION doses of sotrovimab

Ross Lydall@RossLydall
3 days ago
A new treatment for vulnerable patients at greater risk of Covid is being offered at London hospitals from today.

St George’s and Guy’s and St Thomas’s are among the NHS trusts offering the antibody treatment Xevudy, also known as sotrovimab, which can reduce the risk of hospitalisation or death by almost 80 per cent.

British Government bought the week, the cost of a patient hospitalised is something like £2000 a day, nurses ,drugs, consultants etc.